immuno oncology frontiers world miami


Vanessa Lucey

Dr Vanessa Lucey

Associate Director, CRI Venture Fund & Clinical Accelerator, Cancer Research Institute

Vanessa Lucey is the Associate Director of the Anna Maria-Kellen Clinical Accelerator and Venture Fund at the Cancer Research Institute (CRI’s), New York, NY. The Anna-Maria Kellen Clinical Accelerator, the clinical arm of CRI, is a unique academia-nonprofit-industry collaboration model that serves as an “incubator” to accelerate clinical trials of promising new immunotherapy combinations. At CRI, Vanessa developed CRI’s first-of-its-kind the global immuno-oncology (IO) database to track the landscape from discovery to clinic that was recently published in the Annals of Oncology.

Vanessa has over 15 years’ experience in tumor immunology; she received her Ph.D. from Albert Einstein College of Medicine, her postdoctoral fellowship at NYU School of Medicine, where she has authored or co-authored 27 publications. Vanessa also received her M.B.A from Mercy College School of Business.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy